Replies to post #35782 on Manzo Pharmaceuticals Inc. (MNZO)

[bulls9999]

Just saying:

ftp://ftp.fao.org/docrep/fao/009/a0512e/a0512e00.pdf

7. Safety Considerations

7.1 Antimicrobial resistance profiles of probiotics

As with any bacteria, antibiotic resistance exists among some lactic acid bacteria, including probiotic microorganisms (Salminen et al., 1998). This resistance may be related to chromosomal, transposon or plasmid located genes. However, insufficient information is available on situations in which these genetic elements could be mobilized and it is not known if situations could arise where this would become a clinical problem.
There is concern over the use in foods of probiotic bacteria that contain specific drug resistance genes. Bacteria, which contain transmissible drug resistance genes, should not be used in foods.

Currently, no standardized phenotypic methods are available which
are internationally recognized for lactobacilli and bifidobacteria (non-pathogens). The Consultation recognizes the need for the development of standardized assays for the
determination of drug insensitivity or resistance profiles in lactobacilli and bifidobacteria.

The Consultation is aware that plasmids exist in lactobacilli and bifidobacteria, especially in strains isolated from the intestine, which have genes encoding antibiotic resistance. Due to the relevance of this problem, it is suggested that further research be done relating to the antibiotic resistance of lactobacilli and bifidobacteria. When dealing with selection of probiotic strains, it is recommended that probiotic
bacteria should not harbour transmissible drug resistance genes encoding resistance to clinically used drugs. Research is required relating to the antibiotic resistance of lactobacilli and bifidobacteria and the potential for transmission of genetic elements to other intestinal and/or foodborne microorganisms.